Evaluation of Genes Identified by Microarray Analysis in Favorable Neuroblastoma

Overview

Journal Pediatr Surg Int

Specialties General Surgery
Pediatrics

Date 2009 Aug 25

PMID 19701758

Citations 10

Authors

Naomi Kamei

Keiko Hiyama

Hiroaki Yamaoka

Arata Kamimatsuse

Yoshiyuki Onitake

Taijiro Sueda

Eiso Hiyama

Affiliations

Soon will be listed here.

Abstract

Purpose: The biological heterogeneity of neuroblastoma results in a varied outcome ranging from spontaneous regression to fatal tumor progression. Microarray expression profiling and genetic polymorphism arrays may help identify key genes that differ in aggressive neuroblastomas from those observed in tumors associated with a favorable outcome.

Methods: Total RNA was extracted from 16 neuroblastomas obtained from patients who subsequently died of the disease and from 16 favorable neuroblastomas and analyzed using a human whole genome oligomicroarray (55K CodeLink). Genes overexpressed in favorable tumors were subsequently analyzed in 121 neuroblastoma tumors obtained before chemotherapy using real-time RT-PCR. And among these cases, expression levels of these genes were also analyzed in 20 tumors obtained after chemotherapy.

Results: Oligomicroarray analysis revealed the overexpression of 283 genes in favorable tumors that were associated with either regressing or maturing tumors. Three candidate genes, including DHRS3, NROB1, and CYP26A1, were selected that were significantly overexpressed in favorable tumors by quantitative real-time RT-PCR (P < 0.01). No cases with overexpression of all three genes showed poor outcomes. In 20 post-chemotherapeutic tumors, the expression levels of these genes increased in the cases where patients survived but decreased in the fatal cases.

Conclusions: Using microarray expression profiling, we identified genes that exhibit altered gene expression in neuroblastoma tumors associated with a favorable outcome. These candidates warrant further study for use in risk assessment and/or as therapeutic targets in neuroblastoma.

Citing Articles

In Vitro Transfection of Up-Regulated Genes Identified in Favorable-Outcome Neuroblastoma into Cell Lines.

Hiyama Y, Yamaoka E, Fukazawa T, Kojima M, Sotomaru Y, Hiyama E Cells. 2022; 11(19).

PMID: 36231133 PMC: 9564278. DOI: 10.3390/cells11193171.

A Novel Four-Gene Prognostic Signature for Prediction of Survival in Patients with Soft Tissue Sarcoma.

Wu C, Gong S, Osterhoff G, Schopow N Cancers (Basel). 2021; 13(22).

PMID: 34830998 PMC: 8616347. DOI: 10.3390/cancers13225837.

Post-natal all-trans-retinoic acid biosynthesis.

Napoli J Methods Enzymol. 2020; 637:27-54.

PMID: 32359649 PMC: 7357352. DOI: 10.1016/bs.mie.2020.02.003.

Retinol Dehydrogenases Regulate Vitamin A Metabolism for Visual Function.

Sahu B, Maeda A Nutrients. 2016; 8(11).

PMID: 27879662 PMC: 5133129. DOI: 10.3390/nu8110746.

Role of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and Cancer.

Stevison F, Jing J, Tripathy S, Isoherranen N Adv Pharmacol. 2015; 74:373-412.

PMID: 26233912 PMC: 4859867. DOI: 10.1016/bs.apha.2015.04.006.

References

Westermann F, Schwab M . Genetic parameters of neuroblastomas. Cancer Lett. 2002; 184(2):127-47. DOI: 10.1016/s0304-3835(02)00199-4. View

Sawaguchi S, Kaneko M, Uchino J, Takeda T, IWAFUCHI M, Matsuyama S . Treatment of advanced neuroblastoma with emphasis on intensive induction chemotherapy. A report from the Study Group of Japan. Cancer. 1990; 66(9):1879-87. DOI: 10.1002/1097-0142(19901101)66:9<1879::aid-cncr2820660905>3.0.co;2-l. View

Brodeur G, Seeger R, Barrett A, Berthold F, Castleberry R, DAngio G . International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988; 6(12):1874-81. DOI: 10.1200/JCO.1988.6.12.1874. View

Takita J, Ishii M, Tsutsumi S, Tanaka Y, Kato K, Toyoda Y . Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma. Genes Chromosomes Cancer. 2004; 40(2):120-32. DOI: 10.1002/gcc.20021. View

Komatsu M, Hiyama K, Tanimoto K, Yunokawa M, Otani K, Ohtaki M . Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers. Mol Cancer Ther. 2006; 5(3):767-75. DOI: 10.1158/1535-7163.MCT-05-0408. View

Niederreither K, Abu-Abed S, Schuhbaur B, Petkovich M, Chambon P, Dolle P . Genetic evidence that oxidative derivatives of retinoic acid are not involved in retinoid signaling during mouse development. Nat Genet. 2002; 31(1):84-8. DOI: 10.1038/ng876. View

Abu-Abed S, Dolle P, Metzger D, Wood C, MacLean G, Chambon P . Developing with lethal RA levels: genetic ablation of Rarg can restore the viability of mice lacking Cyp26a1. Development. 2003; 130(7):1449-59. DOI: 10.1242/dev.00357. View

De Marco P, Merello E, Mascelli S, Raso A, Santamaria A, Ottaviano C . Mutational screening of the CYP26A1 gene in patients with caudal regression syndrome. Birth Defects Res A Clin Mol Teratol. 2006; 76(2):86-95. DOI: 10.1002/bdra.20225. View

Hiyama K, Otani K, Ohtaki M, Satoh K, Kumazaki T, Takahashi T . Differentially expressed genes throughout the cellular immortalization processes are quite different between normal human fibroblasts and endothelial cells. Int J Oncol. 2005; 27(1):87-95. View

10.

Hiyama E, Hiyama K, Nishiyama M, Reynolds C, Shay J, Yokoyama T . Differential gene expression profiles between neuroblastomas with high telomerase activity and low telomerase activity. J Pediatr Surg. 2003; 38(12):1730-4. DOI: 10.1016/j.jpedsurg.2003.08.042. View

11.

Brodeur G . Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003; 3(3):203-16. DOI: 10.1038/nrc1014. View

12.

Hiyama E, Hiyama K, Yamaoka H, Sueda T, Reynolds C, Yokoyama T . Expression profiling of favorable and unfavorable neuroblastomas. Pediatr Surg Int. 2003; 20(1):33-8. DOI: 10.1007/s00383-003-1077-3. View

13.

Shimada H, Ambros I, Dehner L, Hata J, JOSHI V, Roald B . The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999; 86(2):364-72. View